Suriclone
| Suriclone | |
|---|---|
| Suriclone.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Suriclone is a pharmaceutical drug belonging to the class of cyclopyrrolones, which are known for their anxiolytic and hypnotic properties. It is primarily used in the treatment of anxiety disorders and insomnia.
Pharmacology[edit]
Suriclone acts as a GABA_A receptor agonist, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system. This action results in its calming effects, making it effective for reducing anxiety and inducing sleep.
Mechanism of Action[edit]
Suriclone binds to the benzodiazepine site on the GABA_A receptor, which increases the frequency of chloride ion channel opening events. This leads to hyperpolarization of the neuron and a decrease in neuronal excitability.
Clinical Use[edit]
Suriclone is prescribed for the management of anxiety disorders and short-term treatment of insomnia. It is known for its rapid onset of action and relatively short half-life, which minimizes the risk of daytime sedation.
Side Effects[edit]
Common side effects of Suriclone include drowsiness, dizziness, and headache. In some cases, patients may experience paradoxical reactions such as increased anxiety or agitation.
Contraindications[edit]
Suriclone should not be used in individuals with a history of substance abuse, severe respiratory depression, or myasthenia gravis. Caution is advised in patients with hepatic impairment.
